Omeros (OMER) Tops Q4 Loss Per Share of 52c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Maxim Positive on Omeros' (OMER) Omidria, OMS721; Reaffirms at 'Buy'
March 8, 2016 12:21 PM ESTMaxim reaffirms Omeros (Nasdaq: OMER) at 'Buy' following Q4 results and initiation of its Phase 3 OMS721 program for the treatment of atypical hemolytic uremic syndrome... More
